CACI meets The Bard How Shakespeare can help you navigate the CACI jury instructions, improve your closing arguments, and make you a better lawyer Gregory W. Alarcon From Issue: 2020 July
Problems in products liability likely to arise out of COVID-19 Litigation problems stemming from COVID-19, and common issues surrounding forum non conveniens and failure-to-warn cases David R. LiraChristopher T. Aumais From Issue: 2020 June
COVID-19 business-interruption claims Getting around the “virus” exclusion may require a lot of careful reading as language differs between policies Ricardo Echeverria Michael J. Bidart From Issue: 2020 June
Practice and professionalism considerations in a post-pandemic court From testimony through a mask to video-conference testimony, it’s a brave new world in the courts Valerie Salkin From Issue: 2020 July
Bristol-Myers Squibb’s impact on class actions Bristol-Myers Squibb imposed new limitations on specific jurisdiction in mass actions Robert Fisher From Issue: 2020 June
When that which is supposed to heal, does more harm than good An overview of the doctrinal framework of warning defects as applied to pharmaceutical-injury cases Natali Shabani From Issue: 2020 June
